NPH human insulin
Selected indexed studies
- (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. (Cochrane Database Syst Rev, 2020) [PMID:33166419]
- Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. (Diabetes Obes Metab, 2009) [PMID:19267715]
- Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. (Diabetes Res Clin Pract, 2008) [PMID:18495286]
_Worker-drafted node — pending editorial review._
Connections
NPH human insulin is a side effect of
Sources
- Insulin glargine (Lantus). (2002) pubmed
- Insulin glargine. (2000) pubmed
- (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. (2020) pubmed
- Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. (2007) pubmed
- Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. (2009) pubmed
- Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. (2008) pubmed
- Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. (2005) pubmed
- Human insulin--medical progress? (1983) pubmed
- Human insulin-induced lipoatrophy. (2003) pubmed
- Clinical pharmacology of human insulin. (1993) pubmed